Use of fibrates in the metabolic syndrome: A review

Figure 3 A time line with landmark statin and fibrate randomised control trials (arrows indicate the year of main publication). The fibrate trials are discussed in the review, while the statin trials are only mentioned when relevant. All the statin trials showed that lowering of LDL-C significantly reduced the cardiovascular event chosen as study outcome. 4S: The scandinavian simvastatin survival study; WOSCOPS: West of scotland coronary prevention study; CARE: Cholesterol and recurrent events trial; LIPID: Long-term intervention with pravastatin in ischaemic disease trial; AFCAPS/TexCAPS: Air force/Texas coronary prevention study; HPS: Heart protection study; PROSPER: The prospective study of pravastatin in the elderly at risk; CARDS: Collaborative atorvastatin diabetes study; PROVE-IT: The pravastatin or atorvastatin evaluation and infection therapy trial; IDEAL: The incremental decrease in events through aggressive lipid lowering study; TNT: Treating to new targets trial; SPARCL: The stroke prevention by aggressive reduction in cholesterol levels trial; JUPITER: Justfication for the use of stains in primary prevention: An intervention trial evaluating rosuvastatin trial.